Table 1

Clinical characteristics according to their pathologic diagnosis

Pathologic diagnosisNo. casesMale/female ratioMedian age, y (range)Median transformed (large) T cells, % (range)*TCR-γ gene rearrangement by PCR
AITL 36 1.8 65 (43-87) 30 (12-59) 3/3 
ALK+ ALCL 20 1.0 27 (12-43) 90 (50-95) 5/8 
ALK ALCL 3.0 64 (45-86) 89 (85-94) 2/4 
ATLL 12 5.0 60 (47-80) 45 (17-80) ND 
T/NKCL 14 0.70 33 (28-72) NA NA 
PTCL-NOS 44 2.1 65 (18-65) 58 (7-94) 9/10 
Pathologic diagnosisNo. casesMale/female ratioMedian age, y (range)Median transformed (large) T cells, % (range)*TCR-γ gene rearrangement by PCR
AITL 36 1.8 65 (43-87) 30 (12-59) 3/3 
ALK+ ALCL 20 1.0 27 (12-43) 90 (50-95) 5/8 
ALK ALCL 3.0 64 (45-86) 89 (85-94) 2/4 
ATLL 12 5.0 60 (47-80) 45 (17-80) ND 
T/NKCL 14 0.70 33 (28-72) NA NA 
PTCL-NOS 44 2.1 65 (18-65) 58 (7-94) 9/10 

Not included in this analysis are other 10 cases of PTCL rare entities, including hepatosplenic T-cell lymphoma, mycosis fungoides, enteropathy-associated T-cell lymphoma, and T-cell prolymphocytic leukemia.

AITL indicates angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; NA, not available; ND, not determined; PCR, polymerase chain reaction; PTCL-NOS, peripheral T-cell lymphoma–not otherwise specified; TCR-γ, T-cell receptor-γ; and T/NKCL, T-/natural killer-cell lymphomas.

*

Average calculated from 4 pathologists.

Close Modal

or Create an Account

Close Modal
Close Modal